The trading price of Adma Biologics Inc (NASDAQ:ADMA) closed higher on Tuesday, April 23, closing at $6.54, 5.48% higher than its previous close.
In examining the 52-week price action we see that the stock hit a 52-week high of $6.76 and a 52-week low of $3.06. Over the past month, the stock has gained 3.97% in value.
Adma Biologics Inc, whose market valuation is $1.52 billion at the time of this writing. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by 0.05 per share this quarter, however they have predicted annual earnings per share of 0.3 for current year and 0.5 for next year.
Analysts have forecast the company to bring in revenue of 77.27M for the current quarter, with the likely lows of 76M and highs of 79.7M. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue is 333.87M.
On the technical side, indicators suggest ADMA has a 100% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Buy, while an average of long term indicators suggests that the stock is currently 100% Buy.
A quick review shows that ADMA’s price is currently 4.07% off the SMA20 and 9.98% off the SMA50. The RSI metric on the 14-day chart is currently showing 60.66, and weekly volatility stands at 4.33%. When measured over the past 30 days, the indicator reaches 3.72%. Adma Biologics Inc (NASDAQ:ADMA)’s beta value is currently sitting at 0.43, while the Average True Range indicator is currently displaying 0.25.
To see how Adma Biologics Inc stock has been performing in comparison to its peers in the industry, here are the numbers: ADMA stock’s performance was 5.48% in the latest trading, and 82.68% in the past year.
An evaluation of the daily trading volume of Adma Biologics Inc (NASDAQ:ADMA) indicates that the 3-month average is 2.53 million.
Currently, records show that 226.06 million of the company’s shares remain outstanding. The insiders hold 3.82% of outstanding shares, whereas institutions hold 73.32%. However, since the stock’s price has seen 44.69% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.
